Pharmacokinetics and Safety of Vortioxetine in the Chinese Population.

ABSTRACT:

Introduction

Major depressive disorder (MDD) is associated with a significant burden of disease in China. Awareness and better access to treatments could help alleviate the burden associated with MDD. Because variations have been observed in the pharmacokinetics (PK) of antidepressants across different races and ethnicities, evaluation of the clinical pharmacology of vortioxetine in diverse populations remains important to assess the potential need for dose adjustments.

Methods

Data were pooled from two phase I open-label PK studies in healthy Chinese subjects, and one phase III double-blind noninferiority study in Chinese patients with MDD to describe the PK and safety data for vortioxetine. Doses in these studies ranged from 10 mg (single dose) to 10 and 20 mg (multiple da

SUBMITTER: Miao J 

PROVIDER: S-EPMC6822801 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature